Delivery Technology Solutions Inc. (DTSL.PK)
Delivery Technology Solutions Inc’s, (DTSL.PK) subsidiary Universal Delivery Solutions (UDS) creates the ultimate customer delivery service by branding a One-Number Ordering solution and providing Online Ordering services, as well. UDS, a wholly-owned subsidiary of Delivery Technology Solutions, Inc., fully supports its clients with One -Number Branding (i.e. 888-SUB-TO-GO), One-Number Implementation, One-Number Integration, Online Ordering Integration and Marketing & Promotion Support.
In July, DTSL announced an executed National Vendor Agreement with Doctor’s Associates, Inc. (DAI) the franchisor of SUBWAY(R) Restaurants. The agreement authorizes the introduction of 888-SUB-TO-GO Catering & Delivery services as an optional program for the company. It also allows UDS to explore national catering opportunities amongst large corporations and organizations for consideration by DAI.
The National Catering & Event Management services agreement between UDS and Doctor’s Associates, Inc. enables UDS to offer its corporate catering technology on a private brand basis to all corporate clients, including large organizations and institutions. This technology platform allows clients to easily order and manage catering events at multiple venues serving thousands of meals, and prepare reports detailing every event, from their desktop or laptop.
DTSL also has entered into a catering agreement with one of the largest movie chain of 1400 theaters.
According to DTSL’s CFO Jeff Smith, the company expects to realize a 100% revenue increase in Q3 over Q2 of this year, and another 100% increase in Q4 over Q3. He forecasted 2010 revenue at $400,000 to $500,000, with 2011 revenue expected to more than double this year’s total.
PROT, Proteonomix, Inc., PROT.OB
PROT recently executed a joint venture agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).
The Investor Group has committed to invest $5 million on or before September 10, 2010.
** PROT is scheduling a multi-city European road trip to create additional awareness of the company’s investment opportunity to institutional investors.
Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.
More about PROT at www.proteonomix.com
EnerNOC, Inc. (NASDAQ: ENOC),
EnerNOC, Inc. (NASDAQ: ENOC), a leading provider of clean and intelligent energy management applications, today announced that it has dispatched its demand response network 18 times in California in the past week as a result of high temperatures across the state.
“This summer, demand response has repeatedly served as a key resource to help maintain the real-time balance between electricity supply and demand,” said Tim Healy, EnerNOC’s Chairman and CEO. “EnerNOC’s network continues to meet and, in many cases, exceed expectations by reliably providing clean capacity to the grid when and where it’s needed most.”
When called upon by any of the three investor owned utilities in California, EnerNOC dispatches its network of commercial, institutional, and industrial customers, who respond by reducing non-essential energy usage at their facilities. In exchange for the value these organizations provide to the grid, EnerNOC compensates them with financial payments.
About EnerNOC
EnerNOC unlocks the full value of energy management for utility and commercial, institutional, and industrial (C&I) customers by reducing real-time demand for electricity, increasing energy efficiency, improving energy supply transparency in competitive markets, and mitigating emissions. They accomplish this by delivering world-class energy management applications including DemandSMART(TM), comprehensive demand response; SiteSMART(TM), data-driven energy efficiency; SupplySMART(TM), energy price and risk management; and CarbonSMART(TM), enterprise carbon management. Their Network Operations Center (NOC) continuously supports these applications across thousands of C&I customer sites throughout the world. Working with more than 100 utilities and grid operators globally, they deliver energy, ancillary services, and carbon mitigation resources that provide cost-effective alternatives to investments in traditional power generation, transmission, and distribution.
For more information, visit www.enernoc.com
AVII, AVI BioPharma, Inc. (NASDAQ:AVII)
AVII, a developer of RNA-based drugs, this week announced positive results from two preclinical studies evaluating the therapeutic potential of AVI-7100 against a fully virulent pandemic H1N1 virus, also known as swine flu or swine origin influenza virus. An analysis of the data from the studies demonstrated statistically significant reductions in average viral titer versus a saline control and a control with Tamiflu, a standard of care drug. The studies of AVI-7100, which used AVII’s proprietary PMOplus chemistry, were supported by the Transformational Medical Technologies program (TMT) of the U.S. Department of Defense to identify RNA-based drug candidates against pandemic H1N1 virus. The studies were undertaken as part of a rapid response exercise demonstrating TMT’s ability, in partnership with AVII, to rapidly respond to a real-world emerging viral threat.
AVII, a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology.
To learn more about AVII visit: http://www.antivirals.com
********************************************************************
The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from a third party (Ceiba Network/PenStox) for (30) days of advertising for Delivery Technology Solutions, Inc. (DTSL.PK)
Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
